Overlack Group Acquires Ceepal

The Overlack Group, a chemical distributor for commodities and specialties, acquired Belgian chemical distributor Ceepal. Headquartered in Mönchengladbach, Germany, Overlack has more than 40 operations in 16 countries across Europe and reported annual sales of EUR 645 million in 2016.

Belgium is a very important location in Europe and Ceepal with its position in Overpelt gives Overlack the opportunity to strengthen its presence in Europe. ”We already have a very close network of clients and suppliers in the region due to our locations in Mönchengladbach, Düren and Eindhoven, but we see a lot more potential for our activities in this region,” said Gunther van Baelen, managing director Benelux.

”After more than 50 years, we have established a very good market position and acquired an excellent reputation in Belgium. It is now the right moment for us to go one step further,” said Gil Ceelen, director of Ceepal.

Customers in the region will profit from Overlack’s Europe-wide presence, its broader product portfolio and market knowledge, as well as its company culture, which is based on values such as reliability, flexibility and sustainability.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read

Photo
19.03.2025 • TopicsStrategy

Substances of Concern

The EU Chemicals Strategy for Sustainability (CSS) highlights the shift to a hazard-centric approach in EU chemical regulation, emphasizing 'Substance of Concern' over risk-based measures.

Photo
14.05.2025 • TopicsPharma

Pharma Outlook 2025

The environment for pharma in 2025 is diverse and challenging: New treatment options are being brought to market in ever shorter cycles.